Healthcare Services

Idiopathic Pulmonary Fibrosis Market Developments Influencing Industry Expansion Through 2030

May 29, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Value Of The Idiopathic Pulmonary Fibrosis Market Projected To Expand During 2026–2030?

The idiopathic pulmonary fibrosis market size has experienced robust growth in recent years. Projections indicate an expansion from $4.37 billion in 2025 to $4.66 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.7%. Historically, this growth can be ascribed to factors such as the restricted availability of treatment options for fibrotic lung conditions, an increasing elderly demographic, enhanced clinical diagnosis of IPF, the introduction of nintedanib and pirfenidone, and a rise in hospital-based care for persistent lung ailments.

The idiopathic pulmonary fibrosis market is projected for robust expansion over the coming years, with its size anticipated to reach $6.16 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.2%. This anticipated growth during the forecast period stems from factors such as increased research funding for pulmonary fibrosis, the emergence of advanced antifibrotic medications, a greater reliance on real-world evidence for treatment choices, the broadening reach of online and specialized pharmacy outlets, and heightened public understanding of uncommon respiratory conditions. Key trends expected within this period involve the wider acceptance of antifibrotic treatments, an intensified emphasis on prompt and precise diagnosis, the escalating use of combined drug regimens, the growth of at-home and sustained disease management programs, and enhanced involvement in clinical trials for innovative treatments.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12579&type=smp

What Influential Factors Are Boosting The Idiopathic Pulmonary Fibrosis Market Demand?

The idiopathic pulmonary fibrosis market is anticipated to experience enhanced growth driven by the increasing geriatric population, which comprises elderly or senior citizens within society. As aging leads to structural and functional alterations in the lungs, older individuals become more prone to respiratory ailments like IPF, thereby contributing to the overall demand for IPF treatments. For instance, in January 2024, the US-based non-profit organization, Population Reference Bureau, indicated that the number of Americans aged 65 and older is expected to increase from 58 million in 2022 to 82 million by 2050, marking a 47% rise. This expansion will see this age group’s share of the total U.S. population grow from 17% to 23% over the specified period. Thus, the escalating geriatric population is fueling the growth of the idiopathic pulmonary fibrosis market.

How Is Segment Classification Applied In The Idiopathic Pulmonary Fibrosis Market?

The idiopathic pulmonary fibrosis market covered in this report is segmented –

1) By Drug Type: Nintedanib, Pirfenidone, Other Drug Types

2) By Mode Of Action: Antifibrotic Agents, Tyrosine Kinase Inhibitors, Other Modes Of Action

3) By Route Of Administration: Oral, Parenteral

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Providers

5) By End Users: Hospitals And Clinics, Other End Users

Subsegments:

1) By Nintedanib: Indications, Dosage Forms, Administration Routes

2) By Pirfenidone: Indications, Dosage Forms, Administration Routes

3) By Other Drug Types: Specific Agents Or Classes, Emerging Therapies, Combination Therapies

What Trends Are Influencing The Idiopathic Pulmonary Fibrosis Market Outlook?

Leading companies within the idiopathic pulmonary fibrosis (IPF) market are prioritizing the development of novel products, particularly anti-fibrotic small-molecule inhibitors, to maintain their competitive standing. These inhibitors are a class of pharmaceutical compounds engineered to target and suppress fibrotic processes in the human body. As an illustration, in June 2023, Insilico Medicine, a US-based clinical-stage biotechnology firm leveraging generative artificial intelligence (AI), revealed the commencement of Phase II clinical trials for INS018_055. This compound is notable as the world’s first anti-fibrotic small molecule inhibitor conceived using generative AI. This significant event involved the initial administration of the drug to patients participating in the trial, which is a randomized, double-blind, placebo-controlled investigation designed to assess the safety, tolerability, pharmacokinetics, and initial effectiveness of a 12-week oral dosage of INS018_055 in individuals with idiopathic pulmonary fibrosis (IPF). This inventive method harnesses AI in the process of drug discovery, signaling a prospective leap forward in addressing idiopathic pulmonary fibrosis (IPF) conditions.

Who Are The Firms Contributing To The Idiopathic Pulmonary Fibrosis Market Ecosystem?

Major companies operating in the idiopathic pulmonary fibrosis market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., Gilead Sciences Inc., Toray Industries Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Sun Pharmaceutical Industries Limited, Shionogi and Co. Ltd., Cipla Inc., Zydus Lifesciences Ltd., Chong Kun Dang Pharmaceutical Corp., Kyorin Pharmaceutical Co. Ltd., Galapagos NV, Veracyte Inc., Genentech Inc., FibroGen Inc., GNI Group Ltd., Pliant Therapeutics Inc., Pulmatrix Inc., Galimedix Therapeutics Inc., Avalyn Pharma Inc., MediciNova Inc., Liminal BioSciences Inc., Beijing Continent Pharmaceuticals Company, Galecto Inc.

Access The Complete Idiopathic Pulmonary Fibrosis Market Report:

https://www.thebusinessresearchcompany.com/report/idiopathic-pulmonary-fibrosis-global-market-report

Which Region Stands As The Largest Contributor To The Idiopathic Pulmonary Fibrosis Market?

North America was the largest region in the idiopathic pulmonary fibrosis market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the idiopathic pulmonary fibrosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Idiopathic Pulmonary Fibrosis Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=12579&type=smp

Browse Through More Reports Similar to the Global Idiopathic Pulmonary Fibrosis Market 2026, By The Business Research Company

Non Cystic Fibrosis Bronchiectasis Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/non-cystic-fibrosis-bronchiectasis-global-market-report

Interstitial Lung Disease Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/interstitial-lung-disease-global-market-report

Cystic Fibrosis Cf Therapeutics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/cystic-fibrosis-cf-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795